Abstract: A self-expanding or otherwise expandable artificial valve prostheses for deployment within a body passageway, such as a vessel or duct of a patient. The valve prostheses include a support structure having an outer frame, a supporting member and a valve leaflet. The portion of the valve leaflet is supported by the supporting member and is positioned away from the wall of the body passageway when the device is deployed within the body passageway.

Abstract: The invention relates to a prosthetic valve for regulating flow through a body lumen and delivering a therapeutic agent into said lumen. In one embodiment, the prosthesis includes a frame having an exterior wall, a hollow interior space, a valve member, and at least one aperture through the exterior wall that permits a controlled amount of therapeutic agent loaded into the hollow interior into the surrounding body lumen following implantation. In another embodiment, the prosthesis includes a frame having a groove, a valve member, and therapeutic agent loaded in the groove.

Abstract: The present invention relates to a medical device having a surface with a uniform or non-uniform layer posited thereon that includes a mono- or disaccharide sugar and at least one therapeutic agent. The present invention further relates to materials and a method of making such a medical device and methods of delivering a therapeutic agent.

Abstract: A device for delivering and deploying a radially expandable prosthesis is disclosed and comprises a proximal prosthesis release mechanism having a first resistance and a distal prosthesis release mechanism having a second resistance. The device further comprises an actuation mechanism for actuating the distal and proximal release mechanisms in a single coordinated movement and a biasing compensator for regulating the relationship between the first resistance and the second resistance. Additional aspects of the invention include devices and methods for delivering and deploying a radially expandable prosthesis.

Abstract: This disclosure relates to implantable medical devices coated with a taxane therapeutic agent, such as paclitaxel, in one or more solid form(s) having varying dissolution rates. Particularly preferred coatings comprise amorphous and/or solvated solid forms of taxane therapeutic agents that provide durable coatings that release the taxane over a desired period of time, which can be varied in the absence of a polymer by selecting the type and amount of solid forms of the taxane therapeutic agent in the coating. Other preferred embodiments relate to methods of coating medical devices and methods of treatment. The coatings can provide a sustained release of the taxane therapeutic agent within a body vessel without containing a polymer to achieve the desired rate of paclitaxel elution.

Abstract: This invention relates to a medical device and, in particular, to a prosthesis or stent graft assembly for use within the human or animal body and, more particularly, to the fastening of a stent to the graft material of the stent graft assembly or prosthesis.

Abstract: The invention relates to medical devices coated with zein. The medical device may include further a therapeutic agent in contact with zein. Zein allows the therapeutic agent to be retained on the device during delivery and also controls the elution rate of the therapeutic agent following implantation. The invention further relates to methods of delivering a therapeutic agent on said medical devices as well as their use especially in the form of stents for prevention of restenosis.

Abstract: The present invention provides an implantable medical device comprising a bioactive agent and poly(alkyl cyanoacrylate) polymer. In one embodiment of the invention, the bioactive agent is a water-soluble material, such as an antisense agent.

Abstract: A coated medical device, such as a stent, that elutes a therapeutic agent in a controlled manner is provided. The medical device may be coated with a layer of therapeutic agent and a layer of bioabsorbable elastomer over the layer of therapeutic agent. Methods of manufacturing a coated medical device and of coating a medical device are also provided.

Abstract: Methods of making coated implantable medical devices are provided. The methods include positioning a first layer comprising a bioactive on at least a portion of a structure, and positioning at least one porous layer over the first layer. The at least one porous layer has a thickness adequate to provide a controlled release of the bioactive.

Abstract: Methods of making coated implantable medical devices are provided. The methods include positioning a first layer comprising a bioactive on at least a portion of a structure, and positioning at least one porous layer over the first layer. The at least one porous layer has a thickness adequate to provide a controlled release of the bioactive.

Abstract: An intraluminal device is provided with a porous structure. The porous structure may be loaded with a bioactive substance to treat surrounding tissues after the intraluminal device has been implanted. The porous structure may be made by depositing a metal film on a foam structure using chemical vapor deposition. Porous structures may also be made by sintering or applying a ceramic layer to the intraluminal device. An intraluminal device is also provided with a ceramic material applied to generally straight portions of the device structure but not to portions adapted to bend. One advantage is that the ceramic material is less likely to fracture since it is applied to regions that experience less strain.

Abstract: A coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract; at least one coating layer 16 posited on one surface of the structure; and at least one layer 18 of a bioactive material posited on at least a portion of the coating layer 16, wherein the coating layer 16 provides for the controlled release of the bioactive material from the coating layer. In addition, at least one porous layer 20 can be posited over the bioactive material layer 18, wherein the porous layer includes a polymer and provides for the controlled release of the bioactive material therethrough. Preferably, the structure 12 is a coronary stent. The porous layer 20 includes a polymer applied preferably by vapor or plasma deposition and provides for a controlled release of the bioactive material.

Abstract: Intraluminal devices are provided with an inner cavity. The inner cavity may be loaded with a bioactive substance. Fenestrations extend between an outer surface and the inner cavity. Thus, the bioactive substance may be released from the intraluminal device through the fenestrations.

Abstract: A delivery system is provided with a balloon catheter having a stent mounted thereon. A retention wire is provided to restrain the stent on the balloon of the balloon catheter. The retention wire is coupled to the catheter adjacent the distal end of the stent and adjacent the proximal end of the stent. The retention wire extends along the length of the stent adjacent the outer surface thereof. Thus, the retention wire may restrain the stent from moving longitudinally during inflation of the balloon.

Abstract: A strut, or beam, is provided for intraluminal devices. Strain which is introduced into a stent or other intraluminal device is distributed more evenly along the length of the improved strut by maintaining a substantially constant strain level along the length of an end portion. This may increase fatigue life or improve the performance of devices using the improved strut. The strain along the length of the end portion may be maintained substantially constant by varying a section property of the strut, including the width, thickness, cross-sectional area, material property or other characteristic of the end portion.

Abstract: A stent graft (10) has a tubular body of a biocompatible material and a side arm (20) fastened to the tubular body. A tubular extension piece (24) is sealingly joined to the end of the side arm and extends from it. It can be joined with adhesive or stitching. The extension piece can be formed from an elastomeric biocompatible material such as Thoralon™. The extension piece can have a resilient reinforcement 44 embedded into it and extending longitudinally. The extension piece is tucked back into the side arm during deployment of the stent graft into a body lumen.

Abstract: A beam is provided for intraluminal devices. The beam is defined by a first side surface and a second side surface. The first side surface is tapered at a different rate than the second side surface. One advantage of the beam is that strain which is normally concentrated in adjacent, interconnected bends is redirected onto the length of the beam. This may increase the fatigue life of intraluminal devices or may be used to fashion new structures with improved performance.

Abstract: A sleeve for use in inhibiting leakage of bone cement during a vertebroplasty procedure. The sleeve includes a hollow main body portion and a plunger-like shield disposed at the distal end of the main body portion. The main body portion is sized to be fitted over the cannula of a conventional vertebroplasty assembly through which the cement is injected, and the shield is sized to cover the injection hole in the vertebra, thereby inhibiting leakage of injected cement back through the injection hole.

Abstract: Bioactive-coated medical devices are provided, including coated vascular stents. The medical device coating can include a coating layer posited over at least a portion of the medical device surface, and can include a butyl methacrylate polymer or an ethylene-vinyl acetate copolymer in combination with a bioactive material that can function as both an immunosuppressive agent and an antiproliferative agent. Optionally, multilayer coatings can further include an adhesion promoting layer comprising parylene positioned between the coating layer and the medical device surface, a porous layer comprising butyl methacrylate positioned over at least a portion of the coating layer, or both. The coating layer preferably comprises between about 0.5 and 2.0 ?g/mm2 of the bioactive material on the outer surface of the medical device. The bioactive material can be absorbed into the coating layer, which can have a thickness of between about 0.5 ?m to about 5 ?m.